Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416110 | 0.93 | MAPT (0.36) | RAB9ACSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL4415591 | 0.90 | CA12 (0.37) | KMT2ACYP3A4PTPRB | |
| SCHEMBL4414309 | 0.90 | TK1 (0.36) | ALDH1A1MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL4421554 | 0.89 | SMN1; SMN2 (0.33) | RAB9ASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL4418646 | 0.88 | DDX3X (0.33) | SMN1; SMN2ALDH1A1MAPTGAAMEN1 | |
| SCHEMBL4426611 | 0.85 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4414797 | 0.83 | TK1 (0.37) | PTPRB | |
| SCHEMBL4414566 | 0.83 | CA12 (0.38) | CYP3A4PTPRB | |
| SCHEMBL4411449 | 0.82 | LMNA (0.33) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4412301 | 0.82 | KMT2A (0.33) | MEN1KMT2APOLBPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651642-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-11-04 | — | — | EP | disclosed |
| EP-2099299-A2 | OXAZOLIDINONE DERIVATIVES AND METHODS OF USE | Concert Pharmaceuticals Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008127300-A3 | OXAZOLIDINONE DERIVATIVES AND METHODS OF USE | CONCERT PHARMACEUTICALS INC (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008127300-A2 | OXAZOLIDINONE DERIVATIVES AND METHODS OF USE | CONCERT PHARMACEUTICALS INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1651642-A4 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2006-11-29 | — | — | EP | disclosed |
| EP-1651642-A1 | PNA MONOMER AND PRECURSOR | Panagene Inc. (KR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026930-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009998-A1 | PNA MONOMER AND PRECURSOR | PANAGENE INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026930-A1 | PNA monomer and precursor | RNGTT, POLL, NSUN3 | RAB9A 3664/4885SMN1; SMN2 1750/4885ALDH1A1 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.